SMUG1, single-strand-selective monofunctional uracil-DNA glycosylase 1, 23583
N. diseases: 1034; N. variants: 6
Source: ALL
| Disease | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.100 | Biomarker | disease | BEFREE | A trend toward a significant association was also found between positive 18F-FDG-PET/CT and both Tg-DT <12 months and DTC aggressive subtypes. | 30864903 | 2019 | ||||
|
0.100 | Biomarker | disease | BEFREE | We investigated the usefulness of FDG PET/CT for the early prediction of RAI therapy response in the patients with metastatic differentiated thyroid cancer (DTC). | 31237886 | 2019 | ||||
|
0.100 | GeneticVariation | disease | BEFREE | In this paper we studied the prognostic value of <sup>18</sup>F-FDG PET/CT scan uptake and also of iodine-131 (<sup>131</sup>I) in DTC patients with PM. | 31273354 | 2019 | ||||
|
0.100 | AlteredExpression | disease | BEFREE | The relationship between F-FDG uptake in the pituitary gland and serum TSH levels was evaluated the in DTC patients, and the pituitary F-FDG metabolism was compared in different thyroid status. | 30422898 | 2019 | ||||
|
0.100 | Biomarker | disease | BEFREE | To evaluate the accuracy of 18F-FDG-PET/CT for detection of recurrent and/or metastatic diseases in differentiated thyroid cancer (DTC) patients with thyroglobulin elevation and negative iodine scintigraphy. | 31117054 | 2019 | ||||
|
0.100 | Biomarker | disease | BEFREE | This retrospective study examined whether the primary tumour 18F-FDG uptake features could predict the high-risk of recurrence in differentiated thyroid cancer (DTC) patients. | 30273012 | 2019 | ||||
|
0.100 | Biomarker | disease | BEFREE | Increased uptake of 18F-FDG was observed in anaplastic and poorly differentiated thyroid cancer cells, and PET-positive tumors are more likely to be resistant to 131I treatment. | 30160089 | 2018 | ||||
|
0.100 | Biomarker | disease | BEFREE | Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. | 30015659 | 2018 | ||||
|
0.100 | Biomarker | disease | BEFREE | <sup>18</sup>F-FDG positive metastatic DTC with SUVmax of greater than 4.0 possesses higher probability of non-avidity to radioiodine. | 29531251 | 2018 | ||||
|
0.100 | Biomarker | disease | BEFREE | <sup>18</sup>FDG PET/CT is crucial before neck surgery for nodal recurrence localization in iodine-refractory differentiated or poorly differentiated thyroid cancer (DTC/PDTC). | 30511173 | 2018 | ||||
|
0.100 | Biomarker | disease | BEFREE | Hence, early assessment by <sup>18</sup>F-FDG and <sup>68</sup>Ga-NOTA-PRGD2 PET/CT was effective in the prediction and evaluation of RAIR-DTC treated with apatinib. | 29618578 | 2018 | ||||
|
0.100 | Biomarker | disease | BEFREE | DTC = differentiated thyroid cancer EORTC = European Organization for Research and Treatment of Cancer <sup>18</sup>F-FDG = 2-[fluorine-18] fluoro-2-deoxy-D-glucose FNA = fine-needle aspiration MTC = medullary thyroid cancer PET/CT = positron emission tomography/computed tomography PVE = partial volume effect RAI = radioactive iodine SUV = standardized uptake value Tg = thyroglobulin TSH = thyroid-stimulating hormone. | 27849386 | 2017 | ||||
|
0.100 | Biomarker | disease | BEFREE | Significantly higher TgAb in radioiodine avid tumors with positive <sup>18</sup>F-FDG PET/CT further testify the role of TgAb as surrogate tumor marker in DTC. | 27844413 | 2017 | ||||
|
0.100 | Biomarker | disease | BEFREE | Six patients with iodine-negative and F-FDG-positive metastasized DTC (mean TG, 1616 ng/mL) received 71-93 MBq of the Ga-labeled PSMA ligand and underwent PET/CT at 62 ± 7 minutes p.i.. Tumor accumulation capacity of the tracer and the detection rate of local recurrences and metastases were compared with F-FDG. | 27846003 | 2017 |